Income Statement Exact Sciences Corporation
Stocks
EXAS
US30063P1057
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 104.91 USD | +0.95% |
|
-.--% | +3.30% |
| 25/03 | Exact Sciences Corporation(NasdaqCM:EXAS) dropped from S&P Biotechnology Select Industry Index | CI |
| 25/03 | Exact Sciences Corporation(NasdaqCM:EXAS) dropped from S&P Global BMI Index | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 176.71Cr | 208.43Cr | 249.98Cr | 275.89Cr | 324.7Cr | |||||
Total Revenues | 176.71Cr | 208.43Cr | 249.98Cr | 275.89Cr | 324.7Cr | |||||
Cost of Goods Sold, Total | 46Cr | 57Cr | 65Cr | 84Cr | 98Cr | |||||
Gross Profit | 130.83Cr | 150.99Cr | 184.55Cr | 191.87Cr | 226.28Cr | |||||
Selling General & Admin Expenses, Total | 151.62Cr | 163.99Cr | 163.83Cr | 167.93Cr | 189.05Cr | |||||
R&D Expenses | 39Cr | 39Cr | 43Cr | 43Cr | 52Cr | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 9.5Cr | 9.74Cr | 9.22Cr | - | - | |||||
Other Operating Expenses | - | - | -20.27L | - | - | |||||
Other Operating Expenses, Total | 199.68Cr | 213.08Cr | 215.44Cr | 211.05Cr | 241.3Cr | |||||
Operating Income | -69Cr | -62Cr | -31Cr | -19Cr | -15Cr | |||||
Interest Expense, Total | -1.86Cr | -1.96Cr | -1.94Cr | -2.7Cr | -3.94Cr | |||||
Interest And Investment Income | 3.18Cr | - | 3.27Cr | 3.96Cr | 4.18Cr | |||||
Net Interest Expenses | 1.32Cr | -1.96Cr | 1.33Cr | 1.25Cr | 24.1L | |||||
EBT, Excl. Unusual Items | -68Cr | -64Cr | -30Cr | -18Cr | -15Cr | |||||
Restructuring Charges | - | - | - | - | -2.22Cr | |||||
Merger & Related Restructuring Charges | -14Cr | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | - | -1.94Cr | - | - | - | |||||
Gain (Loss) On Sale Of Assets | - | -1.32Cr | - | - | - | |||||
Asset Writedown | -2.02Cr | -1.6Cr | -6L | -87Cr | -72L | |||||
Other Unusual Items | -63.59L | 5.66Cr | 9.44Cr | 1.25Cr | -2.68Cr | |||||
EBT, Incl. Unusual Items | -84Cr | -63Cr | -20Cr | -103.62Cr | -20Cr | |||||
Income Tax Expense | -25Cr | -90.64L | 24.03L | -73.04L | 40.61L | |||||
Earnings From Continuing Operations | -60Cr | -62Cr | -20Cr | -102.89Cr | -21Cr | |||||
Net Income to Company | -60Cr | -62Cr | -20Cr | -102.89Cr | -21Cr | |||||
Net Income - (IS) | -60Cr | -62Cr | -20Cr | -102.89Cr | -21Cr | |||||
Net Income to Common Incl Extra Items | -60Cr | -62Cr | -20Cr | -102.89Cr | -21Cr | |||||
Net Income to Common Excl. Extra Items | -60Cr | -62Cr | -20Cr | -102.89Cr | -21Cr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -3.48 | -3.54 | -1.13 | -5.59 | -1.1 | |||||
Basic EPS - Continuing Operations | -3.48 | -3.54 | -1.13 | -5.59 | -1.1 | |||||
Basic Weighted Average Shares Outstanding | 17Cr | 18Cr | 18Cr | 18Cr | 19Cr | |||||
Net EPS - Diluted | -3.48 | -3.54 | -1.13 | -5.59 | -1.1 | |||||
Diluted EPS - Continuing Operations | -3.48 | -3.54 | -1.13 | -5.59 | -1.1 | |||||
Diluted Weighted Average Shares Outstanding | 17Cr | 18Cr | 18Cr | 18Cr | 19Cr | |||||
Normalized Basic EPS | -2.46 | -2.27 | -1.03 | -0.61 | -0.49 | |||||
Normalized Diluted EPS | -2.46 | -2.27 | -1.03 | -0.61 | -0.49 | |||||
American Depositary Receipts Ratio (ADR) | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |||||
Supplemental Items | ||||||||||
EBITDA | -51Cr | -42Cr | -10Cr | 2.31Cr | 7.15Cr | |||||
EBITA | -59Cr | -52Cr | -22Cr | -9.66Cr | -5.34Cr | |||||
EBIT | -69Cr | -62Cr | -31Cr | -19Cr | -15Cr | |||||
EBITDAR | -47Cr | -38Cr | -5.65Cr | 6.5Cr | 11Cr | |||||
Total Revenues (As Reported) | - | - | - | - | - | |||||
Effective Tax Rate - (Ratio) | 29.3 | 1.43 | -1.19 | 0.7 | -1.99 | |||||
Current Domestic Taxes | 13.88L | 21.7L | 22.66L | 9L | 15.16L | |||||
Current Foreign Taxes | 48.98L | 11.31L | 25.61L | 18.82L | 39.09L | |||||
Total Current Taxes | 62.86L | 33.01L | 48.27L | 28.15L | 54.25L | |||||
Deferred Domestic Taxes | -25Cr | -1.22Cr | 6L | -99.2L | 2L | |||||
Deferred Foreign Taxes | 54T | -1L | -29.9L | -2L | -15.28L | |||||
Total Deferred Taxes | -25Cr | -1.24Cr | -24.24L | -1.01Cr | -13.64L | |||||
Normalized Net Income | -42Cr | -40Cr | -18Cr | -11Cr | -9.23Cr | |||||
Interest on Long-Term Debt | 1.72Cr | 1.69Cr | 2.43Cr | 3.4Cr | 3.39Cr | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 14Cr | 17Cr | 14Cr | 18Cr | 20Cr | |||||
Marketing Expenses | 19Cr | 24Cr | 18Cr | 21Cr | - | |||||
Selling and Marketing Expenses | 86Cr | 85Cr | 73Cr | 89Cr | 104.73Cr | |||||
General and Administrative Expenses | 65Cr | 79Cr | 91Cr | 79Cr | 84Cr | |||||
Research And Development Expense From Footnotes | 47Cr | 39Cr | 43Cr | 43Cr | 52Cr | |||||
Net Rental Expense, Total | 3.76Cr | 4.48Cr | 4.58Cr | 4.19Cr | 4.2Cr | |||||
Imputed Operating Lease Interest Expense | 23.54L | 28.93L | 28.35L | 33.89L | 49.85L | |||||
Imputed Operating Lease Depreciation | 3.52Cr | 4.19Cr | 4.29Cr | 3.85Cr | 3.7Cr | |||||
Stock-Based Comp., COGS (Total) | - | 1.92Cr | 2.08Cr | 2.05Cr | 1.72Cr | |||||
Stock-Based Comp., R&D Exp. (Total) | - | 3.38Cr | 4.12Cr | 3.97Cr | 3.74Cr | |||||
Stock-Based Comp., S&M Exp. (Total) | - | 6.26Cr | 6.56Cr | 6.82Cr | 6.68Cr | |||||
Stock-Based Comp., G&A Exp. (Total) | - | 9.12Cr | 10Cr | 8.64Cr | 9.63Cr | |||||
Stock-Based Comp., Other (Total) | 25Cr | - | - | - | - | |||||
Total Stock-Based Compensation | 25Cr | 21Cr | 23Cr | 21Cr | 22Cr |
- Stock Market
- Stocks
- EXAS Stock
- Financials Exact Sciences Corporation
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















